Послать статью по эл. почте 
Безопасность и эффективность терапии генно-инженерно-биологическими препаратами ревматоидного артрита
https://doi.org/10.21886/2219-8075-2018-9-3-44-49
Аннотация
В настоящем обзоре литературы рассмотрены вопросы эффективности и безопасности терапии генно-инженерно-биологическими препаратами при ревматоидном артрите. Подробно освещены результаты рандомизированных исследований последних лет. Системный поиск литературы проводился по базам данных Scopus, Web of Science, MedLine, elibrary и др.
Об авторе
Е. А. СтрельцовКазахстан
Стрельцов Евгений Александрович, врач-интерн, внутренние болезни
Список литературы
1. Smolen J.S, Aletaha D., McInnes I.B. Rheumatoid arthritis. // Lancet. – 2016. – V.388(10055). – P.2023-2038. doi: 10.1016/S0140-6736(16)30173-8
2. Vriezekolk J.E., van Lankveld W.G., Geenen R., van den Ende C.H. Longitudinal association between coping and psychological distress in rheumatoid arthritis: a systematic review. // Ann Rheum Dis. – 2011. – V.70(7). – P.1243-50. doi: 10.1136/ard.2010.143271
3. Rodríguez L.A., Tolosa L.B., Ruigomez A., Johansson S., Wallander M.A. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. // Scand J Rheumatol.– 2009. – V. 38(3). – P. 173-7. doi: 10.1080/03009740802448825
4. Gabriel S.E., Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. // Arthritis Res Ther. – 2009. – V. 11(3). – P. 229. doi: 10.1186/ar2669
5. Scott D.L, Wolfe F., Huizinga T.W. Rheumatoid arthritis. // Lancet. – 2010. – V. 376(9746). – P. 1094-108. doi: 10.1016/S0140-6736(10)60826-4
6. Huang C.M., Chen H.H., Chen D.C., Huang Y.C., Liu S.P., Lin Y.J. Rheumatoid arthritis is associated with rs17337023 polymorphism and increased serum level of the EGFR protein. // PLoS One. – 2017. – V. 12(7). – P. e 0180604. doi: 10.1371/journal.pone.0180604
7. Lai C.H., Lai M.S., Lai K.L., Chen H.H., Chiu Y.M. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. // Clin Exp Rheumatol. – 2012. – V. 30(3). – P. 358–363.
8. Kuo C.F., Luo S.F., See L.C., Chou I.J., Chang H.C., Yu K.H. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. // Rheumatol Int. – 2013. - V. 33(2). – P. 355-60. doi: 10.1007/s00296-012-2411-7
9. Zhu H., Xia W., Mo X.B., Lin X., Qiu Y.H., Yi N.J. GeneBased Genome-Wide Association Analysis in European and Asian Populations Identified Novel Genes for Rheumatoid Arthritis. // PLoS One. – 2016. – V. 11(11). – P. e 0167212. doi: 10.1371/journal.pone.0167212
10. McGettrick H.M., Butler L.M., Buckley C.D., Rainger G.E., Nash G.B. Tissue stroma as a regulator of leukocyte recruitment in inflammation. // J Leukoc Biol. – 2012. - V. 91(3). – P. 385-400. doi: 10.1189/jlb.0911458
11. Filer A., Ward L.S.C., Kemble S., Davies C.S., Munir H., Rogers R. Identification of a transitional fibroblast function in very early rheumatoid arthritis. // Ann Rheum Dis.– 2017. - V. 76(12). – P. 2105-2112. doi: 10.1136/annrheumdis-2017-211286
12. Guo Z.Y., Zhang J.X., Wu M., Mei Y.F., Lin X.J., Bu C. Metaanalysis of the association between PADI4 -92C/G polymorphism and rheumatoid arthritis in the Chinese population. // Braz J Med Biol Res. – 2017. – V. 50(10). – P. e 6115. doi: 10.1590/1414-431X20176115
13. Luukkonen J., Pascual L.M., Patlaka C., Lang P., Turunen S., Halleen J. Increased amount of phosphorylated proinflammatory osteopontin in rheumatoid arthritissynovia is associated to decreased tartrate-resistant acid phosphatase 5B/5A ratio. // PLoS One. – 2017. – V. 12(8). – P. e 0182904. doi: 10.1371/journal.pone.0182904
14. Loupasakis K., Kuo D., Sokhi U.K., Sohn C., Syracuse B., Giannopoulou E.G. Tumor Necrosis Factor dynamically regulates the mRNA stabilome in rheumatoid arthritisfi broblastlike synoviocytes. // PLoS One. – 2017. V. 12(7). – P.e0179762. doi: 10.1371/journal.pone.0179762
15. Bustamante M.F., Garcia-Carbonell R., Whisenant K.D., Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. // Arthritis Res Ther. – 2017. – V. 19(1). – P. 110. doi: 10.1186/s13075-017-1303-3
16. Tanaka T., Narazaki M., Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. // FEBS Lett. – 2011. – V.585(23). – P.3699-709. doi: 10.1016/j.febslet.2011.03.023
17. Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. // Ann Rheum Dis. – 2010. – V. 69(1). – P. 88-96. doi: 10.1136/ard.2008.105197
18. Burmester G.R., Rigby W.F., van Vollenhoven R.F., Kay J., Rubbert-Roth A., Kelman A. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. // Ann Rheum Dis. – 2016. – V. 75(6). – P. 1081-91. doi: 10.1136/annrheumdis-2015-207628
19. Yamamoto K., Goto H., Hirao K., Nakajima A., Origasa H., Tanaka K. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. // J Rheumatol. – 2015. – V. 42(8). – P. 1368-75. doi: 10.3899/jrheum.141210
20. Schioppo T., Ingegnoli F. Current perspective on rituximab in rheumatic diseases. // Drug Des Devel Ther. – 2017. - V.11. – P. 2891-2904. doi: 10.2147/DDDT.S139248
21. Tak P.P., Rigby W., Rubbert-Roth A., Peterfy C., van Vollenhoven R.F., Stohl W. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. // Ann Rheum Dis. – 2012. – V. 71(3). – P. 351-7. doi: 10.1136/annrheumdis-2011-200170
22. Chatzidionysiou K., Lie E., Nasonov E., Lukina G., Hetland M.L., Tarp U., van Riel P.L. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and lefl unomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. // Ann Rheum Dis.– 2012. – V. 71(3). – P. 374-7. doi: 10.1136/annrheumdis-2011-200003
23. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. // Arthritis Rheum. – 2006. – V.54(3). – P.711-5.
24. Hayashi S., Suzuki K., Yoshimoto K., Takeshita M., Kurasawa T., Yamaoka K. Early Prognostic Factors Associated with the Efficacy of Infl iximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. // Rheumatol Ther. – 2016. V. 3(1). – P. 155-166.
25. Atteritano M., Mazzaferro S., Mantuano S., Bagnato G.L., Bagnato G.F. Effects of infliximab on sister chromatid exchanges and chromosomal aberration in patients with rheumatoid arthritis. // Cytotechnology.– 2016. – V. 68(2). – P. 313-8. doi: 10.1007/s10616-014-9782-4
26. Th orne C., Bensen W.G., Choquette D., Chow A., Khraishi M., Atkins C.J. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. // Arthritis Care Res (Hoboken). – 2014. – V. 66(8). – P. 1142-51. doi: 10.1002/acr.22290
27. Scott L.J. Etanercept: a review of its use in autoimmune inflammatory diseases. // Drugs. – 2014. – V. 74(12). – P. 1379-410. doi: 10.1007/s40265-014-0258-9
28. Bessette L., Khraishi M., Kivitz A.J., Kaliyaperumal A., Grantab R., Poulin-Costello M. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid ArthritisWho Failed Adalimumab Treatment. // Rheumatol Ther. – 2017. – V. 4(2). – P. 391-404. doi: 10.1007/s40744-017-0079-x
29. Hobbs K., Deodhar A., Wang B., Bitman B., Nussbaum J., Chung J. Randomized, double-blind, placebo-controlled study to evaluate the effi cacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. // Springerplus. - 2015. - V. 4. – P. 113. doi: 10.1186/s40064-015-0895-9
Дополнительные файлы
Для цитирования: Стрельцов Е.А. Безопасность и эффективность терапии генно-инженерно-биологическими препаратами ревматоидного артрита. Медицинский вестник Юга России. 2018;9(3):44-49. https://doi.org/10.21886/2219-8075-2018-9-3-44-49
For citation: Strel’tsov E.A. Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis. Medical Herald of the South of Russia. 2018;9(3):44-49. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-3-44-49
Обратные ссылки
- Обратные ссылки не определены.
